Richard Law
Stock Analyst at Goldman Sachs
(2.25)
# 2,646
Out of 4,876 analysts
64
Total ratings
37.93%
Success rate
1.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $4.56 | +294.74% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.79 | -48.19% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $2.52 | +415.87% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $20.29 | +52.78% | 3 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $31 → $27 | $14.27 | +89.21% | 3 | May 7, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $26.40 | +13.64% | 1 | Apr 8, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $47.64 | +53.23% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $13.53 | +77.38% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $52.67 | +38.60% | 1 | Nov 21, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $4.54 | +142.54% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $11.28 | +174.94% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $16.91 | +177.94% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $46.90 | +34.33% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $44.01 | -15.93% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $9.57 | +694.56% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.21 | +534.92% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.57 | +705.81% | 4 | May 8, 2023 |
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.56
Upside: +294.74%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.79
Upside: -48.19%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $2.52
Upside: +415.87%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $20.29
Upside: +52.78%
Viridian Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $31 → $27
Current: $14.27
Upside: +89.21%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $26.40
Upside: +13.64%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $47.64
Upside: +53.23%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $13.53
Upside: +77.38%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $52.67
Upside: +38.60%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.54
Upside: +142.54%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $11.28
Upside: +174.94%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $16.91
Upside: +177.94%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $46.90
Upside: +34.33%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $44.01
Upside: -15.93%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $9.57
Upside: +694.56%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.21
Upside: +534.92%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.57
Upside: +705.81%